dc.contributor.author |
Saad, HA |
|
dc.contributor.author |
Ali, RS |
|
dc.date.accessioned |
2019-11-23T10:14:05Z |
|
dc.date.available |
2019-11-23T10:14:05Z |
|
dc.date.issued |
2018-05 |
|
dc.identifier.issn |
1420-3049 |
|
dc.identifier.other |
https://doi.org/ |
|
dc.identifier.uri |
https://www.ncbi.nlm.nih.gov/pubmed/29702549 |
|
dc.description |
Accession Number: WOS:000435204000039 |
en_US |
dc.description.abstract |
A novel fused system with three or four fused ringspyridazino[3,4:5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine and pyridazino[3,4:5,6][1,2,4]triazino[3,4-b]pyrimido[4,5-e][1,3,4]thiadiazine was obtained from the starting materials 4(6H)-amino-3-hydrazino-7-(2-thienyl)pyridazino[3,4-e][1,2,4]-triazine 2 and 9-amino-3-(2-thienyl)-2H,8H-pyridazino[3,4:5,6][1,2,4]triazino[3,4-b][1,3,4]thiadiazine-8-carbonitrile 12. Each of the starting compounds was subjected to a number of cyclization reactions to obtain a series of new heterocyclic fused systems, 3-10 and 13-23, via bifunctional reagents. Some of the synthesized compounds were screened against three cell lines including HepG2, HCT-116 and MCF-7 to discover their anticancer activity. The synthesized compounds were characterized depending on their elemental analyses and spectral data. |
en_US |
dc.description.sponsorship |
Taif University, Saudi Arabia
1-438-5765 |
en_US |
dc.description.uri |
https://www.scimagojr.com/journalsearch.php?q=26370&tip=sid&clean=0 |
|
dc.language.iso |
en_US |
en_US |
dc.publisher |
MDPI |
en_US |
dc.relation.ispartofseries |
MOLECULES;Volume: 23 Issue: 5 |
|
dc.relation.uri |
https://cutt.ly/TeVyLZd |
|
dc.subject |
cyclization reactions |
en_US |
dc.subject |
biological applications |
en_US |
dc.subject |
antitumor activity |
en_US |
dc.subject |
:pyridazino[3 ',4 ':5,6][1,2,4]triazino[4,3-b][1,2,4,5]tetrazine |
en_US |
dc.subject |
THIOPHENES |
en_US |
dc.subject |
ANTITUMOR |
en_US |
dc.subject |
IDENTIFICATION |
en_US |
dc.subject |
CYTOTOXIC AGENTS |
en_US |
dc.subject |
CRYSTAL-STRUCTURE |
en_US |
dc.subject |
ANTICANCER DRUGS; ANTI-HIV |
en_US |
dc.subject |
1,2,4-TRIAZINE MOIETY |
en_US |
dc.subject |
:NITROGEN SYSTEMS BEARING |
en_US |
dc.title |
Pharmacological Studies of Unprecedented Fused Derivatives |
en_US |
dc.type |
Article |
en_US |
dc.identifier.doi |
https://doi.org/ |
|
dc.Affiliation |
October University for modern sciences and Arts (MSA) |
|